News

Firdapse approved to treat LEMS patients in Japan

Firdapse (amifampridine) has been approved in Japan to treat people with Lambert-Eaton myasthenic syndrome (LEMS). The therapy will be supplied in the form of oral tablets containing 10 mg of amifampridine, according to Catalyst Pharmaceuticals, the company that holds Firdapse’s licensing rights in North America. In collaboration with…

LEMS deemed respiratory failure cause in woman: Case study

Lambert‐Eaton myasthenic syndrome (LEMS) may, in rare cases, manifest with severe respiratory muscle weakness leading to respiratory failure, researchers noted in a case study. “Establishing the association of LEMS with respiratory disease could lead to timely identification of LEMS, diagnosis of an underlying malignancy (if unknown), and initiation of…

1st LEMS Awareness Day dubbed ‘fantastic’ by founding nonprofit

The inaugural Lambert-Eaton myasthenic syndrome (LEMS) Awareness Day — which will be held each year on March 30 to call attention to the rare autoimmune disorder — was “fantastic,” according to the nonprofit association that created the event. “We appreciate everything everyone did for this first LEMS Awareness Day,…

Man’s cancer complicated by LEMS and another syndrome, SIADH

The rare case of a man with lung cancer complicated by two co-occurring cancer-associated syndromes — Lambert-Eaton myasthenic syndrome (LEMS) and syndrome of inappropriate antidiuretic hormone secretion (SIADH) — was described in a recent report. According to its scientists, only four other documented reports of LEMS and SIADH developing…

DyDo seeks approval of Firdapse for LEMS in Japan

DyDo Pharma is seeking approval of Firdapse (amifampridine) to treat Lambert-Eaton myasthenic syndrome (LEMS) in Japan. A decision from Japan’s Pharmaceuticals and Medical Devices Agency is expected in September. DyDo’s application was submitted in collaboration with Catalyst Pharmaceuticals, which developed Firdapse. DyDo is leading the development…